Merck Minus Medco Sets Ambitious Margin Benchmark: 82% On Pure Rx

Merck's first post-Medco benchmark for the investment community is a reinvigorated pure pharma gross profit margin of 82%

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet